Moneycontrol PRO
HomeNewsBusinessEarningsCipla Q2 preview | Consolidated net profit likely to rise 9% YoY

Cipla Q2 preview | Consolidated net profit likely to rise 9% YoY

In the year-ago quarter, Cipla benefitted from the surge in sales of COVID-19-related drugs

Mumbai / November 03, 2022 / 17:44 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Pharmaceutical major Cipla Limited is expected to report modest growth in earnings when it shares its numbers for the September quarter on November 4 because of a high base in the year-ago period.

    In the year-ago quarter, Cipla benefitted from a surge in sales of COVID-19 -related drugs as infections spiked in the country following the spread of a new variant of the coronavirus.

    The Mumbai-based company is expected to report a 9 percent year-on-year rise in consolidated net profit at Rs 771.3 crore, according to an average of estimates from five brokerage firms polled by Moneycontrol.

    Its topline growth is also expected to be insipid as consolidated revenues are pegged to grow 3.7 percent on-year to Rs 5,723.9 crore, given the high base of the year-ago quarter.

    In India, sales are likely to be up 5-7 percent, driven by higher sales of acute diseases treatment products. The moderate rate of growth is down to the higher share of COVID-19 treatment-linked drugs in the year-ago quarter.

    The US business is likely to be the star of the quarter, with analysts expecting more than 20 percent year-on-year growth in revenues to $170 million led by strong sales of generic Revlimid and other limited-competition products.

    The South African business is likely to report a drop de-growth in sales due to the sharp depreciation in the South African rand against the US dollar during the quarter.

    The operating performance will be lacklustre, with consolidated operating profit likely to remain flat on a year-on-year basis at Rs 1,235.7 crore. The consolidated operating margin in the quarter is also seen stable at 22.2 percent .

    “We continue to maintain that the company's FY2023 EBITDA margin guidance of 21-22 percent is conservative,” Kotak Institutional Equities said in a preview note.

    On November 3, shares of Cipla ended 0.3 percent higher at Rs 1,163.10 on the National Stock Exchange.

    (Disclaimer: The views and investment tips expressed by experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.)

    Chiranjivi Chakraborty
    first published: Nov 3, 2022 05:44 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347
    CloseOutskill Genai